• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by APx Acquisition Corp. I

    6/5/24 6:30:35 AM ET
    $APXI
    Blank Checks
    Finance
    Get the next $APXI alert in real time by email
    8-K
    00-0000000 GRAND CAYMAN false 0001868573 0001868573 2024-05-30 2024-05-30 0001868573 apxi:UnitsEachConsistingOfOneClassAOrdinaryShareParValue0.0001PerShareAndOneHalfOfOneRedeemableWarrant3Member 2024-05-30 2024-05-30 0001868573 apxi:ClassAOrdinarySharesParValue0.0001PerShare1Member 2024-05-30 2024-05-30 0001868573 apxi:WarrantEachWholeWarrantExercisableForOneClassAOrdinaryShareFor11.50PerShare2Member 2024-05-30 2024-05-30

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 30, 2024

     

     

    APX Acquisition Corp. I

    (Exact name of registrant as specified in its charter)

     

     

     

    Cayman Islands   001-41125   N/A

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    714 Westview Avenue

    Nashville, TN 37205

    (Address of principal executive offices, including zip code)

    Registrant’s telephone number, including area code: (202) 465-5882

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Units, each consisting of one Class A Ordinary Share, par value $0.0001 per share, and one-half of one Redeemable Warrant   APXIU   The NASDAQ Stock Market LLC
    Class A Ordinary Shares, par value $0.0001 per share   APXI   The NASDAQ Stock Market LLC
    Warrant, each whole warrant exercisable for one Class A Ordinary Share for $11.50 per share   APXIW   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 3.01

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On May 30, 2024, APx Acquisition Corp. I (the “Company”), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that since the Company had not yet filed its Form 10-K for the period ended December 31, 2023 nor had it filed its Form 10-Q for the period ended March 31, 2024, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5250(c)(1) (the “Rule”), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission through the EDGAR System (the “Notice”). The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 60 calendar days, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, the Company will have 180 calendar days from the referenced Form 10-K’s due date, or until September 27, 2024, to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel.

    The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. The Company intends to take action to submit a plan to regain compliance within the 60 calendar days submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with the Rule within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq Global Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Rule. In addition, if the Company does not meet the Rule’s requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a hearings panel.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      APX ACQUISITION CORP. I
    Dated: June 5, 2024   By:  

    /s/ Kyle Bransfield

      Name:   Kyle Bransfield
      Title:   Chief Executive Officer
    Get the next $APXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Bransfield Kyle P disposed of 100,000 units of Class A ordinary shares and acquired 100,000 units of Class A ordinary shares (SEC Form 4)

    4 - APx Acquisition Corp. I (0001868573) (Issuer)

    7/31/24 9:45:03 PM ET
    $APXI
    Blank Checks
    Finance

    Bransfield Kyle P disposed of 800,000 units of Class A ordinary shares and acquired 800,000 units of Class A ordinary shares (SEC Form 4)

    4 - APx Acquisition Corp. I (0001868573) (Issuer)

    3/25/24 5:00:06 PM ET
    $APXI
    Blank Checks
    Finance

    Bransfield Kyle P converted options into 3,342,188 units of Class A ordinary shares (SEC Form 4)

    4 - APx Acquisition Corp. I (0001868573) (Issuer)

    2/8/24 9:05:08 PM ET
    $APXI
    Blank Checks
    Finance

    $APXI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by APx Acquisition Corp. I

    SCHEDULE 13G - APx Acquisition Corp. I (0001868573) (Subject)

    1/7/25 4:31:51 PM ET
    $APXI
    Blank Checks
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by APx Acquisition Corp. I

    SCHEDULE 13G/A - APx Acquisition Corp. I (0001868573) (Subject)

    1/7/25 11:47:26 AM ET
    $APXI
    Blank Checks
    Finance

    SEC Form 8-K filed by APx Acquisition Corp. I

    8-K - APx Acquisition Corp. I (0001868573) (Filer)

    12/16/24 4:05:25 PM ET
    $APXI
    Blank Checks
    Finance

    $APXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units

    NASHVILLE, Tenn., Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice"). The Company subsequently submitted a plan to regai

    11/1/24 5:48:00 PM ET
    $APXI
    Blank Checks
    Finance

    APX Acquisition Corp. I Reports 10-K Delinquency Notice

    NASHVILLE, Tenn., June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financi

    6/5/24 1:33:00 PM ET
    $APXI
    Blank Checks
    Finance

    APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

    NASHVILLE, Tenn., March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ:APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to the approval of APx's shareholders and other customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nas

    3/26/24 8:25:00 AM ET
    $APXI
    Blank Checks
    Finance

    $APXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by APx Acquisition Corp. I

    SC 13G - APx Acquisition Corp. I (0001868573) (Subject)

    11/14/24 8:51:50 PM ET
    $APXI
    Blank Checks
    Finance

    SEC Form SC 13G filed by APx Acquisition Corp. I

    SC 13G - APx Acquisition Corp. I (0001868573) (Subject)

    11/14/24 4:18:23 PM ET
    $APXI
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by APx Acquisition Corp. I

    SC 13G/A - APx Acquisition Corp. I (0001868573) (Subject)

    10/16/24 9:19:30 AM ET
    $APXI
    Blank Checks
    Finance